GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Helix BioPharma Corp (OTCPK:HBPCF) » Definitions » NonCurrent Deferred Liabilities

HBPCF (Helix BioPharma) NonCurrent Deferred Liabilities : $0.00 Mil (As of Jan. 2025)


View and export this data going back to 2008. Start your Free Trial

What is Helix BioPharma NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Helix BioPharma's non-current deferred liabilities for the quarter that ended in Jan. 2025 was $0.00 Mil.

Helix BioPharma NonCurrent Deferred Liabilities Historical Data

The historical data trend for Helix BioPharma's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Helix BioPharma NonCurrent Deferred Liabilities Chart

Helix BioPharma Annual Data
Trend Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Helix BioPharma Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Helix BioPharma NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Helix BioPharma's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Helix BioPharma Business Description

Traded in Other Exchanges
Address
40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4
Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidate is L-DOS47 for Tumor Defence Breaker is in clinical trials for pancreatic cancer.